Initially, anti-MDA5 autoantibody was identified in a cohort of East Asian patients with clinically amyopathic myositis (81%) and rapidly progressive ILD (74%) [5], with >90% of rapidly progressive interstitial lung disease (RP-ILD) cases and 84% mortality occurring within the first 6 months of disease onset [6]. Here, IFIH1 is linked to interstitial lung disease.